PMID: 9663925Jul 15, 1998Paper

Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats

Journal of Hypertension
R L WebbM de Gasparo

Abstract

To investigate the chronic effects of combined administration of an angiotensin II receptor antagonist (valsartan) and an angiotensin converting enzyme inhibitor (benazeprilat) on blood pressure and heart rate in conscious telemetered spontaneously hypertensive rats. Blood pressure and heart rate were monitored (by radiotelemetry) during 2-week infusions of 0.5-10 mg/kg valsartan per day and 0.5-10 mg/kg benazeprilat per day, alone or in combination, into conscious spontaneously hypertensive rats. Also, responses of blood pressure in conscious spontaneously hypertensive rats to exogenous angiotensin I and II were determined. Synergistic antihypertensive effects were observed when valsartan and benazeprilat were coadministered at submaximal monotherapy doses in the range 0.5-1.5 mg/kg per day. For all combination groups, the area over the curve (mmHg x days) for lowering of blood pressure was significantly greater (synergy) than that predicted from the sum of the monotherapy responses. Combination therapy abrogated pressor responses to angiotensin I more effectively than did comparable doses of the monotherapies. These results demonstrate that combination therapy aimed at interrupting operation of the renin-angiotensin system si...Continue Reading

References

Feb 1, 1990·Journal of Cardiovascular Pharmacology·V MooserH R Brunner
Apr 11, 1991·American Journal of Hypertension·P C WongP B Timmermans
Jun 1, 1989·Hypertension·P F MentoB M Wilkes
May 1, 1985·Hypertension·J NussbergerH R Brunner
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·M B ZimmermanJ A Norman
Jan 1, 1965·Transactions of the Association of American Physicians·J de ChamplainR Boucher
Jan 1, 1982·British Journal of Pharmacology·E K Potter
Dec 1, 1993·Journal of Cardiovascular Pharmacology·M K BazilR L Webb
Sep 1, 1993·Peptides·K KoharaC M Ferrario
Nov 1, 1993·Journal of Hypertension·A Husain
Oct 10, 1997·Hypertension·C M FerrarioD I Diz

❮ Previous
Next ❯

Citations

Jun 27, 2009·Archives of Pharmacal Research·Chang-Yong ShinChang-Seon Myung
Oct 2, 2002·European Journal of Pharmacology·Moez RekikAbdel A Abdel-Rahman
Jun 28, 2002·Acta histochemica·Betül KalenderEkrem Erek
Aug 8, 2002·Diabetes Technology & Therapeutics·Geoffrey BonerMark E Cooper
Feb 24, 2000·Clinical and Experimental Hypertension : CHE·M M El-Mas, A A Abdel-Rahman
Feb 14, 2006·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Peter Karl Jacobsen
Mar 1, 2001·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Trefor Morgan
May 2, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Trefor MorganLea Delbridge
Sep 28, 2002·Journal of Cardiovascular Pharmacology·Kazunori YoshidaMasahiro Kohzuki
Mar 2, 2006·Journal of Hypertension·Michel AziziNorman K Hollenberg
Jan 14, 2004·The Journal of Pharmacology and Experimental Therapeutics·Mark C KowalaJohn E Macor
Oct 12, 2000·Journal of Cardiovascular Pharmacology·M A CavasinO A Carretero
Jul 14, 2010·Journal of Hypertension·Joep H M van EschA H Jan Danser
Apr 13, 2004·Journal of Hypertension·Joël Ménard, Michel Azizi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.